New Two-Year ORENCIA(R) (abatacept) AIM Data Presented At Annual EULAR Congress
April 24th 2008 10:13 pm
Data presented at the 2006 European League Against Rheumatism (EULAR) annual congress look at the Bristol-Myers Squibb Company (NYSE: BMY) rheumatoid arthritis (RA) usage ORENCIA(R) (abatacept) and measure up to clinical benefits, by technique of well as patient-reported outcome, through two years of treatment contained by RA patients who hold an sparse feedback to methotrexate (MTX).(1) These background be segment of a Phase III examination group as AIM (Abatacept in Inadequate responders to Methotrexate), which integrated an introductory one-year, double-blind length and a subsequent open-label new building phase.(2) Radiographic grades (Genant, et al) be presented autonomously.(3) Details from the Long-Term Extension of the AIM Trial In an analysis of the AIM Long-Term Extension (LTE) (Kremer, et al) clinical outcomes were dais on top of the percent of acquaintances achieve ACR 20, 50 and 70 rack up and about (indicating a 20 percent, 50 percent and 70 percent upturn in signs and symptom of rheumatoid arthritis, respectively) and the Disease Activity Score 28 (DAS28) based on C-Reactive Protein (CRP). Patient-reported outcomes using the Health Assessment Questionnaire Disability Index (HAQ-DI) and the Short-Form (SF-36) were also measured. The HAQ-DI be in nearer times owned to appraise geographical drive. The SF-36, which measured health-related talent of energy and the physical and emotional piece re-evaluation scores (PCS and MCS, respectively), were report.
In the setup immoderation near ORENCIA(R) (abatacept) plus MTX through two years, nigh on 82 percent of patients spit out ACR 20 response in Year 1 and 80 percent achieved ACR 20 responses in Year 2; 54 percent of patients achieved ACR 50 responses in Year 1 and 56 percent achieved ACR 50 responses in Year 2; 32 percent of patients achieved ACR 70 responses in Year 1 and 34 percent achieved ACR 70 responses in Year 2.
Those who switch from placebo plus MTX to ORENCIA plus MTX at the embark on of the extension phase achieved matching ACR responses consequent one year of treatment compare with those reception ORENCIA plus MTX all for two years (ACR 20: 78 percent vs. 80 percent; ACR 50: 58 percent vs. 56 percent; and, ACR 70: 32 percent vs. 34 percent, for the 1-year of treatment vs 2-years of treatment, respectively).
Rates of DAS28 scores of smaller number than 2.6 were similar at two years, regardless of initial randomization. At Year 1, 25.4 percent of patients in the ORENCIA plus MTX group achieved DAS28 scores of less than 2.6 compared to 2.5 percent in the placebo plus MTX group. By Year 2, 30.9 percent of those continuing to receive ORENCIA plus MTX achieved DAS28 scores of less than 2.6 versus 32.6 percent of patients who had be in the placebo group and after received ORENCIA plus MTX in the LTE.
Patient-reported outcomes were measured using the SF-36. At Year 1 for PCS, patients in the ORENCIA plus MTX group had a anticipate mould from baseline of 9.7 compared to 6.6 in the placebo plus MTX group. At Year 2 for PCS, patients in the ORENCIA plus MTX group had a mean change from baseline of 10.6 compared to 10.5 who had been in the placebo plus MTX group and then received ORENCIA plus MTX in the LTE.
At Year 1 for MCS, patients in the ORENCIA plus MTX group had a mean change from baseline of 7.3 compared to 6.4 in the placebo plus MTX group. At Year 2 for MCS, patients in the ORENCIA plus MTX group had a mean change from baseline of 7.2 compared to 8.3 who had been in the placebo plus MTX group and then received ORENCIA plus MTX in the LTE.
Improvements in physical function of greater than or correspondent to 0.3 part using HAQ-DI were maintain through two years in the LTE.
Patients in the initial double-blind phase of the trial received a unbendable dose of ORENCIA(R) (abatacept) (based on element compass approximating 10mg/kg; n433) or placebo (n219) on Days 1, 15 and 29, and all 4 weeks thereafter, mutually with to MTX, for one year. Of these enrollees, 539 individuals from both the group treated with ORENCIA and the group treated with placebo enter the open-label extension phase of the trial and were treated with a fixed dose of ORENCIA (based on weight range approximating 10 mg/kg every 4 weeks) while continuing treatment with MTX after six months during the double-blind phase and in the long-term extension phase, adjustment of disease-modifying rheumatic drugs (DMARDs) and dose of DMARDs were allowed at the discretion of the investigator.
Important Safety Information crudely ORENCIA Before receiving treatment with ORENCIA, individuals should notify their healthcare provider if they right now are receiving treatment with a TNF antagonist (e.g., Enbrel(R), Humira(R), Remicade(R)) or Kineret(R) to treat rheumatoid arthritis (RA). These individuals may have a better stake of experiencing important infectivity if they receive treatment with ORENCIA together with other biologic medication for RA. People receiving treatment with ORENCIA also should notify their healthcare providers if they are taking any other medications including hormones, over-the-counter medicine, vitamins, insert or herbal products.
Individuals should question their risk of infection with their healthcare providers. People should say to their healthcare providers of any infections that they may have, including infections in a specific site in or on the unit (such as an embark on thwack a hole in or sore), or an infection that involve the intact body (such as the flu), as these category of infection could walk off individuals at risk for serious tenderloin effects from ORENCIA. Additionally, individuals should alert their healthcare providers if they have infections that won’t alleviate or have history of intermittent infections.
People who have had tuberculosis (TB), have had a up fleece look at for TB, or who lately have been in affix letter with someone who have had TB should inform their healthcare providers.
If these individuals come along any of the symptoms of TB (i.e., a desiccate cough that doesn’t affix to, weight disappearance, confusion, dark sweat, etc.), they should notify their healthcare providers recklessly. Before initiate treatment with ORENCIA(R), healthcare providers may fasten your eye on done individuals for TB or perform a skin test to discover the attendance of TB.
Additionally, individuals should inform their healthcare providers if they are planned to have surgery, or if they recently received a booster or are scheduled to receive any vaccination. Before receiving ORENCIA(R) (abatacept), people should alert their healthcare providers if they have a long-ago of incurable obstructive pulmonary (lung) virus (COPD), as taking ORENCIA may interrupt their COPD symptoms to worsen.
Pregnant women, women planning to receive expectant or women thinking about becoming pregnant should inform their healthcare providers prior to starting treatment with ORENCIA. It be not known if display to ORENCIA pose risks to unborn infant. Women should alert their healthcare providers if they are breastfeeding, as these individuals will involve to emit bedside light on any to breastfeed or to receive treatment with ORENCIA, but not both.
Like all medicines that affect the immune complex, ORENCIA can cause serious side effects, including serious infections, allergic reaction and malignancies. Individuals receiving treatment with ORENCIA are at increased risk for nascent infections including pneumonia and other infections cause via virus, germs or fungus. Individuals should immediately contact their healthcare providers if they grain queasy or suffer any infection during treatment with ORENCIA. Allergic reactions to ORENCIA psychotherapy may also outgrowth up. These reactions are typically kind or allay, collectively occur in the preliminary 24 hours of an infusion and can refinement hives, bulging obverse, eyelids, jaws, argot, oesophagus or obstacle breathing. There have been two serious allergic reactions reported in individuals following ORENCIA infusion. There have also been cases of abiding kind of cancer in individuals receiving ORENCIA. The role of ORENCIA in the improvement of cancer is not known.
The more rife side effects with ORENCIA are headache, upper respiratory tract infection, rise throat and nausea.
For abounding prescribe talk, oblige drop by or Dosing and Administration ORENCIA(R) (a fully human soluble fusion protein) is administered as a 30- hardly visible intravenous infusion at a fixed dose based on weight range approximating 10 mg/kg at morning 0, 2 weeks, 4 weeks, and every 4 weeks thereafter. Infusion reactions were sophisticated in nine percent of people treated with ORENCIA(R) (abatacept) and in six percent of people treated with placebo. The greatest recurrently reported infusion-related adverse dealings (1 percent to 2 percent) were wooziness, headache, and hypertension. In clinical trial, premedications were not enforced.
However, take over medical upgrading measures for the treatment of hypersensitivity reactions should be untaken for instantaneous pay envelope in the prevalence of a hostile response.
About ORENCIA ORENCIA, accepted by the U.S. Food and Drug Administration (FDA) on December 23, 2005, is indicate for reducing signs and symptoms, inducing primary clinical response, slow the improvement of structural wrong, and on the boost up physical function in adults with relatively to utterly active rheumatoid arthritis who have had an inadequate response to one or more DMARDs, such as MTX or TNF antagonists. ORENCIA may be used as monotherapy or concomitantly with DMARDs except for TNF antagonists. ORENCIA should not be administered concomitantly with TNF antagonists and is nutty for use concomitantly with anakinra.
ORENCIA, a selective modulator of a co-stimulatory sign required for full T-cell activation, was discovered and work by Bristol-Myers Squibb Company.
About Rheumatoid Arthritis Rheumatoid arthritis is a systemic, chronic, autoimmune disease characterized by inflammation in the bin liner of joint (or synovium), cause joint damage with chronic rounded pain, stiffness and swelling.(4) RA cause predetermined range of motion and lessening function as a wrap up result of studied joints losing their profile and alignment.(4) RA affect about 1 percent of the world’s population,(5) including over and done two million people in the United States.(6) The prerequisite is more common in women, who side for 75 percent of patients diagnose with RA.(6) Bristol-Myers Squibb is a unanimous pharmaceutical and associated robustness help products good folks whose search is to extend and enhance human life.
References (1) Kremer JM, Emery P, Becker JP, Aranda R, Teng J, Li T, Westhovens R. Abatacept provide crucial and permanent benefits in clinical and patient-reported outcomes through 2 years in patients with rheumatoid arthritis and an inadequate response to methotrexate: the long-term extension of the AIM trial. Poster introduction FRI0134, Abstract 705 at: 2006 European League Against Rheumatism (EULAR) annual congress. Amsterdam, Netherlands, June 21-24, 2006.
(2) Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski K, Li T, Zhiyu G, Becker JP, Westhovens R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Annals of Internal Medicine 2006;144:865-876.
(3) Genant HK, Peterfy C, Westhovens R, Becker JP, Aranda R, Teng J, Kremer JM. Abatacept sustain inhibition of radiographic progression over 2 years in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate (MTX): results from the long-term extension (LTE) of the AIM trial. Oral presentation OP0015, Abstract 1566 at: 2006 European League Against Rheumatism (EULAR) annual congress. Amsterdam, Netherlands, June 21-26, 2006.
(4) Guidelines for the guidance of rheumatoid arthritis; 2002 update. Arthritis & Rheumatism. 2002;46(2):328-346.
(5) Lee DM and Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-911.
(6) American College of Rheumatology Web locality. Rheumatoid arthritis. /public/factsheets/ra_new.asp?audpat#3 Accessed December 20, 2005.